bile duct neoplasms

Summary

Summary: Tumors or cancer of the BILE DUCTS.

Top Publications

  1. ncbi A review and update on cholangiocarcinoma
    Matthew J Olnes
    Department of Internal Medicine, Johns Hopkins Bayview Medical Center and Johns Hopkins School of Medicine, Baltimore, MD, USA
    Oncology 66:167-79. 2004
  2. pmc Risk factors for cholangiocarcinoma
    Gia L Tyson
    Section of Gastroenterology at the Michael E DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX 77030, USA
    Hepatology 54:173-84. 2011
  3. ncbi Cholangiocarcinoma
    Shahid A Khan
    Liver Unit, Division of Medicine, St Mary s Hospital Campus, Faculty of Medicine, Imperial College London, London, UK
    Lancet 366:1303-14. 2005
  4. ncbi The epidemiology of cholangiocarcinoma
    Yasser Shaib
    Sections of Gastroenterology and Health Services Research, The Houston Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas 77030, USA
    Semin Liver Dis 24:115-25. 2004
  5. pmc Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
    Vikram Deshpande
    Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114, USA
    BMC Cancer 11:60. 2011
  6. pmc Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document
    S A Khan
    Liver Unit, Department of Medicine A, Imperial College School of Medicine, St Mary s Hospital Campus, South Wharf Street, London W2 1PG, UK
    Gut 51:VI1-9. 2002
  7. pmc Liver fluke induces cholangiocarcinoma
    Banchob Sripa
    Department of Pathology, Khon Kaen University, Khon Kaen, Thailand
    PLoS Med 4:e201. 2007
  8. pmc Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study
    Tania M Welzel
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Clin Gastroenterol Hepatol 5:1221-8. 2007
  9. ncbi Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States
    T Patel
    Division of Gastroenterology, Scott and White Clinic, Texas A and M University System Health Science Center, College of Medicine, Temple, TX 76508, USA
    Hepatology 33:1353-7. 2001
  10. ncbi Cholangiocarcinoma and Clonorchis sinensis infection: a case-control study in Korea
    Dongil Choi
    Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50, IlWon Dong, Kangnam Ku, Seoul 135 710, South Korea
    J Hepatol 44:1066-73. 2006

Research Grants

Detail Information

Publications300 found, 100 shown here

  1. ncbi A review and update on cholangiocarcinoma
    Matthew J Olnes
    Department of Internal Medicine, Johns Hopkins Bayview Medical Center and Johns Hopkins School of Medicine, Baltimore, MD, USA
    Oncology 66:167-79. 2004
    ..Particular focus is on recent studies into the cellular and molecular pathogenesis of the disease, recent chemotherapy trials, and newer methods of staging and screening for this devastating malignancy...
  2. pmc Risk factors for cholangiocarcinoma
    Gia L Tyson
    Section of Gastroenterology at the Michael E DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX 77030, USA
    Hepatology 54:173-84. 2011
    ..Therefore, the consistent use of a more refined classification would allow a better understanding of risk factors for CC...
  3. ncbi Cholangiocarcinoma
    Shahid A Khan
    Liver Unit, Division of Medicine, St Mary s Hospital Campus, Faculty of Medicine, Imperial College London, London, UK
    Lancet 366:1303-14. 2005
    ..However, controversy exists over the type and positioning of biliary stents. Photodynamic treatment is a new palliative technique that might improve quality of life...
  4. ncbi The epidemiology of cholangiocarcinoma
    Yasser Shaib
    Sections of Gastroenterology and Health Services Research, The Houston Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas 77030, USA
    Semin Liver Dis 24:115-25. 2004
    ..Some data, however, point to a potential role for chronic liver disease, hepatitis C, and probably hepatitis B infections in the development of ICC...
  5. pmc Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
    Vikram Deshpande
    Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114, USA
    BMC Cancer 11:60. 2011
    ..The genetics of advanced biliary tract cancers (BTC), which encompass intra- and extra-hepatic cholangiocarcinomas as well as gallbladder carcinomas, are heterogeneous and remain to be fully defined...
  6. pmc Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document
    S A Khan
    Liver Unit, Department of Medicine A, Imperial College School of Medicine, St Mary s Hospital Campus, South Wharf Street, London W2 1PG, UK
    Gut 51:VI1-9. 2002
  7. pmc Liver fluke induces cholangiocarcinoma
    Banchob Sripa
    Department of Pathology, Khon Kaen University, Khon Kaen, Thailand
    PLoS Med 4:e201. 2007
  8. pmc Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study
    Tania M Welzel
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Clin Gastroenterol Hepatol 5:1221-8. 2007
    ..Because the etiology of both tumors is poorly understood, a population-based case-control study was conducted to examine the association of ECC and ICC with preexisting medical conditions...
  9. ncbi Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States
    T Patel
    Division of Gastroenterology, Scott and White Clinic, Texas A and M University System Health Science Center, College of Medicine, Temple, TX 76508, USA
    Hepatology 33:1353-7. 2001
    ..8%, respectively. In conclusion, there has been a marked increase in the incidence and mortality from intrahepatic cholangiocarcinoma in the United States in recent years. This tumor continues to be associated with a poor prognosis...
  10. ncbi Cholangiocarcinoma and Clonorchis sinensis infection: a case-control study in Korea
    Dongil Choi
    Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50, IlWon Dong, Kangnam Ku, Seoul 135 710, South Korea
    J Hepatol 44:1066-73. 2006
    ..The authors conducted a hospital-based case-control study to evaluate the role of Clonorchis sinensis infection as a risk factor for the development of cholangiocarcinoma (CC), including extrahepatic CC, in Korea...
  11. pmc Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment
    Boris Blechacz
    Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 48:308-21. 2008
  12. pmc Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection
    Y Kitagawa
    First Department of Surgery, Nagoya University School of Medicine, Nagoya, Japan
    Ann Surg 233:385-92. 2001
    ..However, the fact that long-term survival is possible despite pN2 or pM1 disease encourages the authors to perform an aggressive surgical procedure with extended lymph node dissection in selected patients with hilar cholangiocarcinoma...
  13. ncbi Optimum palliation of inoperable hilar cholangiocarcinoma: comparative assessment of the efficacy of plastic and self-expanding metal stents
    Ramu P Raju
    Department of Gastroenterology, Hepatology, and Nutrition, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1466, Houston, TX 77030 4009, USA
    Dig Dis Sci 56:1557-64. 2011
    ..Endoscopic retrograde biliary drainage (ERBD) with plastic or self-expanding metal stents (SEMS) is often performed for palliative care for cholangiocarcinoma...
  14. ncbi Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation
    Zichen Zhang
    Division of Cellular and Molecular Pathogenesis, Department of Pathology, Medical College of Virginia Campus of Virginia Commonwealth University, Richmond, VA, USA
    Hepatology 39:1028-37. 2004
    ..Our in vivo results further suggest celecoxib might have potential therapeutic or chemopreventive value against ChC...
  15. pmc Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma
    W R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg 234:507-17; discussion 517-9. 2001
    ..To analyze resectability and survival in patients with hilar cholangiocarcinoma according to a proposed preoperative staging scheme that fully integrates local, tumor-related factors...
  16. ncbi Clonorchiasis: an update
    H J Rim
    Department of Paraitology, College of Medicine, Korea University, Seoul 136 705, Korea
    J Helminthol 79:269-81. 2005
    ..The most effective regimen is 25 mg kg(-1) three times daily (total dose, 75 mg kg(-1)) administered orally at 5- to 6-h intervals over a single day. Prevention and control measures are also discussed...
  17. ncbi Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100)
    Banchob Sripa
    Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand
    World J Gastroenterol 11:3392-7. 2005
    ..To establish and characterize a new cholangiocarcinoma cell line from a patient living in the Opisthorchis viverrini (O. viverrini) endemic area of Northeast Thailand...
  18. ncbi Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin
    Mina Komuta
    Department of Morphology and Molecular Pathology, University Hospitals Leuven, Leuven, Belgium
    Hepatology 47:1544-56. 2008
    ..05), while albumin was downregulated in CLC (P = 0.007) toward K19-negative HCCs. Comparison of CLC with K19-positive HCCs indicated a high homology...
  19. pmc Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver
    A Tannapfel
    Institute of Pathology, University of Leipzig, Liebigstr 26, 04103 Leipzig, Germany
    Gut 47:721-7. 2000
    ..Inactivation of the tumour suppressor gene p16 (CDKN2/MTS-1/INK4A) and K-ras mutations are among the most frequent genetic alterations in human malignancies...
  20. pmc Cholangiocarcinoma: lessons from Thailand
    Banchob Sripa
    Department of Pathology, Faculty of Medicine, Thailand
    Curr Opin Gastroenterol 24:349-56. 2008
    ..To present the background of liver fluke-associated cholangiocarcinoma in Thailand focusing on recent epidemiological data and pathogenesis of this bile duct cancer...
  21. ncbi High lifetime risk of cancer in primary sclerosing cholangitis
    Marian M H Claessen
    Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    J Hepatol 50:158-64. 2009
    ..Primary sclerosing cholangitis (PSC) patients are at risk for developing cholangiocarcinoma (CCA) and colorectal carcinoma (CRC). Our aim was to assess the risk of malignancies and their influence on survival...
  22. ncbi Photodynamic therapy for non-resectable perihilar cholangiocarcinoma
    Tobias Kiesslich
    Department of Internal Medicine I, Paracelsus Medical University Salzburg, Muellner Hauptstrasse 48, 5020, Salzburg, Austria
    Photochem Photobiol Sci 8:23-30. 2009
    ..The local tumour ablation and correction of obstructive cholestasis with PDT will allow for novel multimodal strategies to treat cholangiocarcinoma...
  23. ncbi Animal PET for thioacetamide-induced rat cholangiocarcinoma: a novel and reliable platform
    Chun Nan Yeh
    Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, 5, Fu Hsing Street, Kwei Shan, Taoyuan, Taiwan
    Mol Imaging Biol 10:209-16. 2008
    ..Our objective was to evaluate the feasibility of animal PET in detecting CCA in the setting of the TAA rat model...
  24. ncbi Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas
    Eric T Shinohara
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 74:1191-8. 2009
    ..The purpose of this study was to examine the role of adjuvant and palliative RT in the treatment of EHC in a large patient population...
  25. ncbi Constitutive Notch2 signaling induces hepatic tumors in mice
    Michael T Dill
    Department of Biomedicine, Hepatology Laboratory, University of Basel, Basel, Switzerland
    Hepatology 57:1607-19. 2013
    ..CCC formation in patients and DEN(N2ICD) mice is accompanied by re-expression of hepatocyte nuclear factor 4α(HNF4α), possibly indicating dedifferentiation of BECs...
  26. ncbi Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma
    C Möbius
    Department of Surgery II, University of Leipzig, Leipzig, Germany
    Eur J Surg Oncol 33:1025-9. 2007
    ..In extrahepatic cholangiocarcinoma, the VEGF expression and microvessel density have rarely been investigated...
  27. ncbi Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma
    Natini Jinawath
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Japan
    Hepatology 44:1025-38. 2006
    ....
  28. ncbi Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study
    Yasser H Shaib
    Section of Health Services Research, Michael E DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Gastroenterology 128:620-6. 2005
    ..In this case-control study, we used the Surveillance, Epidemiology, and End Results-Medicare database to evaluate the prevalence of known risk factors for intrahepatic cholangiocarcinoma and explore other potential risk factors...
  29. ncbi Magnetic resonance imaging of cholangiocarcinoma
    Riccardo Manfredi
    Department of Radiology, A Gemelli University Hospital, Rome, Italy
    Semin Liver Dis 24:155-64. 2004
    ..The main reason for surgical/imaging discrepancy is represented by the microscopic diffusion along the mucosa and in the perineural space...
  30. pmc Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors
    Jesper B Andersen
    Laboratory of Experimental Carcinogenesis, National Institutes of Health, Bethesda, Maryland 20892 4262, USA
    Gastroenterology 142:1021-1031.e15. 2012
    ..Cholangiocarcinoma is a heterogeneous disease with a poor outcome that accounts for 5%-10% of primary liver cancers. We characterized its genomic and genetic features and associated these with patient responses to therapy...
  31. ncbi Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism
    Gabriel Frampton
    Department of Internal Medicine, Texas A and M Health Science Center College of Medicine, Temple, TX 76504, USA
    Gut 61:268-77. 2012
    ..The growth factor, progranulin, is overexpressed in a number of tumours. The study aims were to assess the expression of progranulin in cholangiocarcinoma and to determine its effects on tumour growth...
  32. ncbi Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany
    Thomas von Hahn
    Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule, Hannover Medical School, Hannover, Germany
    Scand J Gastroenterol 46:1092-8. 2011
    ..We aimed to provide epidemiological data on recent trends in liver-related mortality, specifically mortality from hepatobiliary malignancies, in Germany...
  33. ncbi Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction
    Atif Saleem
    Department of Internal Medicine, Mayo Clinic, College of Medicine, Rochester, Minnesota, USA
    Gastrointest Endosc 74:321-327.e1-3. 2011
    ..Self-expandable metal stents (SEMSs) are used for palliation of malignant biliary obstruction...
  34. ncbi Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells
    Hiroaki Sugiyama
    Department of Gastroenterology, Institute of Clinical Medicine, University of Tsukuba Graduate School of Comprehensive Human Sciences, Tsukuba, Ibaraki, Japan
    J Gastroenterol 46:779-89. 2011
    ....
  35. ncbi Cholangiocarcinoma
    Tushar Patel
    Texas A and M Health Science Center College of Medicine, Scott and White Clinic, Temple, TX 76508, USA
    Nat Clin Pract Gastroenterol Hepatol 3:33-42. 2006
    ....
  36. ncbi Anti-tumor activity of all-trans retinoic acid-incorporated glycol chitosan nanoparticles against HuCC-T1 human cholangiocarcinoma cells
    Kyu Don Chung
    Department of Anesthesiology and Pain Medicine, College of Medicine, The Catholic University, Seoul 137 701, Republic of Korea
    Int J Pharm 422:454-61. 2012
    ..Our results suggested that RA-incorporated GC nanoparticles is a promising vehicles for RA delivery to HuCC-T1 cholangiocarcinoma cells...
  37. ncbi Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies
    Edgar Ben-Josef
    Department of Radiation Oncology, Division of Hematology Oncology, University of Michigan, UH B2C490, 1500 E Medical Center Dr, Ann Arbor, MI 48109 0010, USA
    J Clin Oncol 23:8739-47. 2005
    ..A phase II trial was conducted to determine if high-dose radiation with concurrent hepatic arterial floxuridine would improve survival in patients with unresectable intrahepatic malignancies...
  38. ncbi Management of hilar biliary strictures
    Alberto Larghi
    Digestive Endoscopy Unit, Universita Cattolica del Sacro Cuore, Rome, Italy
    Am J Gastroenterol 103:458-73. 2008
    ..As an alternative, a multi-stent technique with endoscopic placement of an increasing number of stents over time until complete resolution of the stricture has been proposed...
  39. ncbi Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor)
    Sander Dinant
    Department of Surgery, Academic Medical Center, P O Box 22700, 1100, DE, Amsterdam, The Netherlands
    Ann Surg Oncol 13:872-80. 2006
    ..The aim of this study was to assess the outcome of a 15-year evolution in the surgical treatment of Klatskin tumors...
  40. ncbi Liver transplantation for cholangiocarcinoma
    Charles B Rosen
    Division of Transplantation Surgery, Mayo Clinic, Rochester, MN 55905, USA
    Transpl Int 23:692-7. 2010
    ....
  41. ncbi Initial performance profile of a new 6F self-expanding metal stent for palliation of malignant hilar biliary obstruction
    Jennifer Chennat
    Center for Endoscopic Research and Therapeutics, Section of Gastroenterology, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Gastrointest Endosc 72:632-6. 2010
    ..A 6F endoscopic biliary self-expanding metal stent (SEMS) has been newly introduced for intended simultaneous side-by-side bilateral deployment in hilar malignant obstruction...
  42. ncbi Surgical treatment of Klatskin tumor: liver resection versus transplantation
    Gernot M Kaiser
    Department of General, Visceral, and Transplantation Surgery, University Hospital Essen, University Duisburg Essen, Essen, Germany
    Hepatogastroenterology 57:1337-40. 2010
    ..Our objective was to evaluate liver transplantation as a treatment option for Klatskin tumor. Results for transplanted patients suffering from hilar cholangiocarcinoma were therefore compared to patients after hemihepatectomy...
  43. ncbi Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2
    Hyunho Yoon
    Therapeutic Antibody Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305 806, Republic of Korea
    Biochem Biophys Res Commun 405:333-7. 2011
    ..The results indicate that AKT and ERK1/2 signaling mediate chemoresistance in the cells and could be important therapeutic targets for overcoming chemoresistance in ICC...
  44. ncbi Effect of surfactant on 5-aminolevulinic acid uptake and PpIX generation in human cholangiocarcinoma cell
    Chung Wook Chung
    Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea
    Eur J Pharm Biopharm 80:453-8. 2012
    ..Cotreatment with the surfactant resulted in an increased intracellular ALA level, PpIX formation, and phototoxicity...
  45. ncbi Photodynamic therapy for unresectable cholangiocarcinoma
    Yutaka Tomizawa
    Department of Medicine, University of Pittsburgh Medical Center, 5230 Center Avenue, Pittsburgh, PA 15232, USA
    Dig Dis Sci 57:274-83. 2012
    ..PDT has also been reported to have a favorable outcome as adjuvant and neoadjuvant therapy for CC. Although accumulated data and local expertise are limited, PDT can be regarded as a standard palliative therapy for unresectable CC...
  46. ncbi Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma
    Jun Sato
    Department of Organ Regenerative Surgery, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960 1295, Japan
    J Hepatobiliary Pancreat Sci 18:700-11. 2011
    ..We aimed to investigate the potential clinical role of gemcitabine metabolism-related genes in the gemcitabine sensitivity of cholangiocarcinoma and identify and characterize novel gemcitabine resistance-related genes...
  47. ncbi The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma
    Motoko Sasaki
    Department of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan
    Lab Invest 88:873-82. 2008
    ..Therefore, the overexpression of polycomb-group proteins Bmi1 and EZH2 is associated with the malignant progression of HCC, thereby reflecting the aggressive biological behavior in HCC and HC-CC...
  48. ncbi Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma
    Junji Komori
    Department of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
    Hepatology 47:888-96. 2008
    ..Moreover, immunostaining for AID was detectable in 16 of 20 bile epithelia in the tissues underlying primary sclerosing cholangitis...
  49. ncbi CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma
    Mitsuo Shimada
    Department of Surgery, Institute of Health Biosciences, The University of Tokushima, Kuramoto 3 18 15, Tokushima 770 8503, Japan
    J Gastroenterol 45:896-902. 2010
    ..However, no one has investigated the role of CD133 in intrahepatic cholangiocarcinoma (IHCC). The aim of this study was to clarify the clinical role of CD133 expression in IHCC...
  50. ncbi Endoscopic bilateral metal stent placement for advanced hilar cholangiocarcinoma: a pilot study of a newly designed Y stent
    Jung Hyun Lee
    Department of Internal Medicine, Pusan National University College of Medicine, Seo Gu, Busan, Korea
    Gastrointest Endosc 66:364-9. 2007
    ....
  51. ncbi Selective MRCP and CT-targeted drainage of malignant hilar biliary obstruction with self-expanding metallic stents
    Martin L Freeman
    Division of Gastroenterology, Hennepin County Medical Center, Minneapolis, Minnesota 55415, USA
    Gastrointest Endosc 58:41-9. 2003
    ..This study evaluated outcomes of selective MRCP and CT-targeted drainage with self-expanding metallic stents...
  52. ncbi A comparison of covered and uncovered Wallstents for the management of distal malignant biliary obstruction
    Won Jae Yoon
    Department of Internal Medicine, Seoul National University College of Medicine, 28 Yeongeon dong, Jongno gu, Seoul 110 744, Korea
    Gastrointest Endosc 63:996-1000. 2006
    ..The efficacy and complications of covered self-expandable metal stents (SEMS) remain controversial...
  53. ncbi Epidemiology of liver cancer: an overview
    Petcharin Srivatanakul
    National Cancer Institute, Rajchathewee 10400, Bangkok Thailand
    Asian Pac J Cancer Prev 5:118-25. 2004
    ..The interaction between genes and the environment and the interplay of environmental factors, which include diet and other lifestyle parameters, illustrate the complexity underlying susceptibility...
  54. pmc Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma
    Kanuengnuch Kosriwong
    Graduate School, Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand
    World J Gastroenterol 17:1631-41. 2011
    ..To investigate trefoil factor (TFF) gene copy number, mRNA and protein expression as potential biomarkers in cholangiocarcinoma (CCA)...
  55. ncbi Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy
    Alphonse E Sirica
    Division of Cellular and Molecular Pathogenesis, Department of Pathology, Virginia Commonwealth University School of Medicine, Medical College of Virginia Campus, Richmond, VA 23298 0297, USA
    Hepatology 41:5-15. 2005
    ....
  56. ncbi Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest
    Chang Han
    Department of Pathology, University of Pittsburgh School of Medicine, Presbyterian University Hospital, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Cancer Res 64:1369-76. 2004
    ....
  57. pmc Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice
    Xiaoling Xu
    Genetics of Development and Disease Branch, NIDDK, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 116:1843-52. 2006
    ..These findings elucidate the relationship between SMAD4 and PTEN and extend our understanding of CC formation...
  58. ncbi Cholangiocarcinoma
    Konstantinos N Lazaridis
    Division of Gastroenterology and Hepatology, Center for the Basic Research in Digestive Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastroenterology 128:1655-67. 2005
  59. ncbi Plastic versus self-expanding metallic stents for malignant hilar biliary obstruction: a prospective multicenter observational cohort study
    David G Perdue
    University of Minnesota, Minneapolis, MN, USA
    J Clin Gastroenterol 42:1040-6. 2008
    ..There are few comparative data as to whether plastic or self-expanding metallic stents are preferable for palliating malignant hilar biliary obstruction...
  60. ncbi Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome
    Michael T Milano
    Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Int J Radiat Oncol Biol Phys 59:445-53. 2004
    ..To assess the efficacy and toxicity of intensity-modulated radiotherapy (IMRT) in pancreatic and bile duct (cholangiocarcinoma) malignancies...
  61. ncbi Endoscopic palliation of patients with biliary obstruction caused by nonresectable hilar cholangiocarcinoma: efficacy of self-expandable metallic Wallstents
    John L S Cheng
    Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
    Gastrointest Endosc 56:33-9. 2002
    ..The aim of this study was to evaluate the efficacy of an endoscopically inserted self-expandable metal stent for treatment of biliary obstruction caused by nonresectable hilar cholangiocarcinoma...
  62. ncbi Y-shaped endoscopic bilateral metal stent placement for malignant hilar biliary obstruction: prospective long-term study
    Jae Chul Hwang
    Department of Gastroenterology, Ajou University School of Medicine, San 5, Woncheon dong, Yongtong Gu, Suwon, Republic of Korea
    Scand J Gastroenterol 46:326-32. 2011
    ..The aim of our study was to evaluate the technical and clinical efficacies of endoscopic bilateral metal stenting using a biliary Y-stent for the management of malignant hilar obstruction...
  63. ncbi Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study
    Marianne E J Ortner
    Division de Gastro entérologie et Hépatologie, BH 10N, Centre Hospitalier Universitaire Vaudois, CH 1011 CHUV Lausanne, Switzerland
    Gastroenterology 125:1355-63. 2003
    ..This prospective, open-label, randomized, multicenter study with a group sequential design compared PDT in addition to stenting (group A) with stenting alone (group B) in patients with NCC...
  64. ncbi Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy
    F Donato
    Cattedra di Igiene, Universita di Brescia, Italy
    Cancer Causes Control 12:959-64. 2001
    ..We carried out a case-control study to assess the association between ICC and hepatitis B and C virus (HBV and HCV) infections, alcohol intake, and hepatolithiasis in Brescia, North Italy...
  65. ncbi Newly designed large cell Niti-S stent for malignant hilar biliary obstruction: a pilot study
    Hirofumi Kogure
    Department of Gastroenterology, Faculty of Medicine, University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo, 113 8655, Japan
    Surg Endosc 25:463-7. 2011
    ..This study evaluated the feasibility and efficacy of the Niti-S large cell D-type biliary stent (LCD) with a uniform large cell for both uni- and bilateral drainage of malignant hilar biliary obstruction...
  66. pmc Actual long-term outcome of extrahepatic bile duct cancer after surgical resection
    Jin Young Jang
    Department of Surgery, Seoul National University College of Medicine, Chongno Gu, Korea
    Ann Surg 241:77-84. 2005
    ..The objectives of this study were to analyze the actual long-term outcome after the surgical resection of extrahepatic bile duct cancer and to identify the characteristics shared by long-term survivors (5 years or longer)...
  67. ncbi Chemoradiation in patients with unresectable extrahepatic and hilar cholangiocarcinoma or at high risk for disease recurrence after resection : Analysis of treatment efficacy and failure in patients receiving postoperative or primary chemoradiation
    D Habermehl
    Department of Radiation Oncology, University Hospital of Heidelberg, Germany
    Strahlenther Onkol 188:795-801. 2012
    ....
  68. ncbi Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis
    Norihisa Ishimura
    Division of Gastroenterology and Hepatology, Mayo Clinic, College of Medicine, Rochester, Minnesota 55905, USA
    Gastroenterology 128:1354-68. 2005
    ..Because cholangiocarcinomas arise in a background of inflammation and express the inflammatory mediator inducible nitric oxide synthase (iNOS), we aimed to determine whether iNOS expression alters Notch expression and signaling...
  69. ncbi Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States
    Tania M Welzel
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, EPS 7084, MSC 7234 6120 Executive Blvd, Bethesda, MD 20892, USA
    J Natl Cancer Inst 98:873-5. 2006
    ..001)...
  70. pmc A case of mucin producing liver metastases with intrabiliary extension
    Hirotaka Tokai
    Department of Transplantation and Digestive Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1 7 1 Sakamoto, Nagasaki 852 8051, Japan
    World J Gastroenterol 12:4918-21. 2006
    ..Therefore, the tumor was diagnosed as a metastatic adenocarcinoma from colonic cancer. Liver metastases of colorectal adenocarcinoma sometimes invade the Glisson's triad and grow along the biliary ducts...
  71. pmc Anticancer activities against cholangiocarcinoma, toxicity and pharmacological activities of Thai medicinal plants in animal models
    Tullayakorn Plengsuriyakarn
    Thailand Center of Excellence for Drug Discovery and Development TCEDDD, Thammasat University, Pathumthani, Thailand
    BMC Complement Altern Med 12:23. 2012
    ..Chemotherapy of cholangiocarcinoma (CCA), a devastating cancer with increasing worldwide incidence and mortality rates, is largely ineffective. The discovery and development of effective chemotherapeutics is urgently needed...
  72. pmc Cholangiocarcinoma: a compact review of the literature
    Yucel Ustundag
    Department of Internal Medicine, Gastroenterology Clinic, School of Medicine, Hacettepe University, Ankara 06100, Turkey
    World J Gastroenterol 14:6458-66. 2008
    ..We need more prospective randomized controlled trials to evaluate the role of the new emerging therapies for CC patients...
  73. ncbi Risk factors for cholangiocarcinoma in Khon Kaen, Thailand: a nested case-control study
    Kirati Poomphakwaen
    Dept of Epidemiology, Faculty of Public Health, Mahidol University, Bangkok, Thailand
    Asian Pac J Cancer Prev 10:251-8. 2009
    ..99, 95% CI= 1.04-8.62). The findings suggest that O. viverrini infestation is the strongest risk factor for development of cholangiocarcinoma and also suggests decrease in risk among individuals who consume more fruit...
  74. ncbi Single-session endoscopic bilateral y-configured placement of metal stents for hilar malignant biliary obstruction
    Yoshihide Kanno
    Department of Gastroenterology, Sendai City Medical Center, Sendai, Japan
    Dig Endosc 23:91-6. 2011
    ..The aim of this study was to evaluate the efficacy and safety of endoscopic bilateral biliary metal stent placement for hilar malignant obstruction...
  75. ncbi Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells
    Norihisa Ishimura
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 290:G129-36. 2006
    ..These data demonstrate that TRAIL promotes cell migration and invasion via a NF-kappaB-dependent pathway in human cholangiocarcinoma cell lines, an observation that has a potential negative implication for TRAIL in cancer therapy...
  76. ncbi Usefulness of slimmer and open-cell-design stents for endoscopic bilateral stenting and endoscopic revision in patients with hilar cholangiocarcinoma (with video)
    Jeong Yeol Kim
    Department of Internal Medicine, Pusan National University School of Medicine and Medical Research Institute, Yangsan, Korea
    Gastrointest Endosc 70:1109-15. 2009
    ....
  77. ncbi Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases
    Myung Ah Lee
    Division of Oncology, Department of Internal Medicine, Catholic University of Medical College, Seoul, Korea
    Jpn J Clin Oncol 34:547-50. 2004
    ..We investigated the efficacy and toxicity of the combination of gemcitabine and cisplatin as second-line chemotherapy in four patients with advanced, progressive intrahepatic cholangiocarcinoma...
  78. ncbi Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients
    David J Rea
    Department of Surgery, Division of Gastroenterologic and General Surgery, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Arch Surg 139:514-23; discussion 523-5. 2004
    ..Major hepatectomy, bile duct resection, and regional lymphadenectomy for hilar cholangiocarcinoma are associated with actual long-term (>5 years) survival...
  79. ncbi Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis
    Kelly Burak
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 99:523-6. 2004
    ..5 yr, which is dramatically higher than the rates in the general population. Variceal bleeding is a major risk factor for the later development of CCA...
  80. ncbi Intrahepatic biliary cystadenoma: role of cyst fluid analysis and surgical management in the laparoscopic era
    Alan Koffron
    Department of Surgery, Northwestern University Medical School, Chicago, IL, USA
    Surgery 136:926-36. 2004
    ..However, the role of CA 19-9 and CEA in the diagnosis of IBC and the role of LS in the management of IBC have not been previously defined...
  81. pmc A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells
    Christian D Fingas
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    Hepatology 52:550-61. 2010
    ..JP1584 also reduced TRAIL-mediated CCA cell migration and invasion in vitro. Finally, in a syngeneic rat orthotopic CCA model, JP1584 administration reduced MMP7 messenger RNA levels and extrahepatic metastases...
  82. ncbi Clinicopathologic study on cholangiolocellular carcinoma
    K Shiota
    Department of Pathology, Kurume University School of Medicine, Kurume 830 0011, Japan
    Oncol Rep 8:263-8. 2001
    ..It is suggested that CLC cells might be derived from Hering's canal or stem cells which have the intermediate features between hepatocytes and bile duct epithelium...
  83. pmc Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy
    Kawin Leelawat
    Department of Surgery, Rajavithi Hospital, Bangkok 10400, Thailand
    BMC Gastroenterol 9:30. 2009
    ..Previous studies have demonstrated that matrix metalloproteinase (MMP)-7 and MMP-9 are frequently expressed in cholangiocarcinoma specimens...
  84. ncbi A comparison of right versus left hepatic duct endoprosthesis insertion in malignant hilar biliary obstruction
    A A Polydorou
    Department of Gastroenterology, University College, Middlesex Hospital Medical School, London, UK
    Endoscopy 21:266-71. 1989
    ..When dealing with a patient with a Type II or III HBO, we would recommend single endoscopic endoprosthesis insertion into the technically most accessible obstructed system. This would achieve adequate palliation in 84% of the patients...
  85. pmc Longterm outcome of photodynamic therapy compared with biliary stenting alone in patients with advanced hilar cholangiocarcinoma
    Young Koog Cheon
    Department of Internal Medicine, Digestive Disease Centre, Konkuk University School of Medicine, Seoul, South Korea
    HPB (Oxford) 14:185-93. 2012
    ....
  86. ncbi The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review
    Laura W Lamps
    University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Adv Anat Pathol 10:39-43. 2003
    ....
  87. ncbi Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature
    M Shimoda
    Department of Gastroenterological and Hepatobiliary Surgery, Dokkyo University School of Medicine, Mibu, Tochigi, Japan
    Liver Transpl 7:1023-33. 2001
    ..Three-year disease-free survival is achieved in approximately 30% of patients. These outcomes can be improved by applying strict selection criteria based on prognostic variables identified in this study...
  88. ncbi Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a case-control study in China
    Lian yuan Tao
    Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
    Liver Int 30:215-21. 2010
    ..The risk factors for cholangiocarcinoma are incompletely defined in China, especially for intrahepatic cholangiocarcinoma (ICC). We evaluated the risk factors for both ICC and extrahepatic cholangiocarcinoma (ECC)...
  89. ncbi Surgical treatment of hilar cholangiocarcinoma in the "new era": the Nagoya University experience
    Tsuyoshi Igami
    Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya 466 8550, Japan
    J Hepatobiliary Pancreat Sci 17:449-54. 2010
    ..To review our surgical experience with hilar cholangiocarcinoma in the "new era."..
  90. ncbi ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions
    Kanenori Endo
    Department of Pathology, Medical College of Virginia Campus of Virginia Commonwealth University, Richmond, VA 23298, USA
    Hepatology 36:439-50. 2002
    ..The results also suggest ERBB-2 and COX-2 as potentially important targets relevant to chemoprevention or adjunct therapy of ChC...
  91. ncbi T-configured dual stent placement in malignant biliary hilar duct obstructions with a newly designed stent
    Chang Won Kim
    Department of Radiology, Busan National University College of Medicine, Korea
    J Vasc Interv Radiol 15:713-7. 2004
    ..To evaluate the technical success and clinical efficacy of T-configured dual stent placement in the management of malignant biliary hilar duct obstructions with a newly designed stent...
  92. ncbi Transplantation for cholangiocarcinoma: when and for whom?
    David J Rea
    Division of Transplantation Surgery, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Surg Oncol Clin N Am 18:325-37, ix. 2009
    ..This approach has achieved results superior to standard surgical therapy, with 72% 5-year survival for patients with unresectable disease...
  93. ncbi Crisscross-configured dual stent placement for trisectoral drainage in patients with advanced biliary hilar malignancies
    Jae Ik Bae
    Department of Radiology, Ajou University School of Medicine, Suwon, Republic of Korea
    J Vasc Interv Radiol 19:1614-9. 2008
    ..To evaluate technical success and clinical efficacy of crisscross-configured dual biliary stent implantation in patients with a biliary hilar tumor extending beyond the segmental ducts...
  94. ncbi Endoscopic stenting for malignant biliary obstruction
    K L Cheung
    Department of Surgery, University of Hong Kong, Queen Mary Hospital
    Arch Surg 130:204-7. 1995
    ..To evaluate the results of endoscopic stenting in patients with malignant biliary obstruction...
  95. ncbi Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301)
    Yoshitaka Inaba
    Aichi Cancer Center Hospital, Nagoya, Japan
    Am J Clin Oncol 34:58-62. 2011
    ..We conducted a phase I/II study to ascertain the recommended dose (RD) of hepatic arterial infusion using gemcitabine (GEM) for ICC and to assess the efficacy and safety...
  96. ncbi Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma
    Kelvin Hong
    The Russell H Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Semin Oncol 37:110-7. 2010
    ..In this report, we attempt to employ an evidence-based approach to critically review and comprehend the current role and future potential of intra-arterial therapies for ICC...
  97. ncbi Outcome of second interventions for occluded metallic stents in patients with malignant biliary obstruction
    Wiriyaporn Ridtitid
    Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand
    Surg Endosc 24:2216-20. 2010
    ..This study was designed to determine the efficacy and outcome of PS, SEMS, and PTBD for patients with occluded SEMS...
  98. ncbi Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas
    Yoh Zen
    Department of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan
    Hepatology 44:1333-43. 2006
    ..In conclusion, biliary papillary tumors may be the biliary counterpart (intraductal papillary neoplasm of the bile duct) of IPMN-P...
  99. ncbi Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets
    Alphonse E Sirica
    Department of Pathology, Medical College of Virginia Campus of Virginia, Commonwealth University, Richmond, Virginia 23298 0297, USA
    Semin Liver Dis 22:303-13. 2002
    ..These findings suggest that aberrant expression of ERBB-2 and COX-2 is a common feature of human and rat cholangiocarcinomas and that targeting of both proteins may prove useful as a therapeutic strategy for this lethal cancer...
  100. ncbi Serum and bile markers for cholangiocarcinoma
    Oliver Nehls
    Department of Internal Medicine I, University Hospital Tubingen, Germany
    Semin Liver Dis 24:139-54. 2004
    ..g., pancreatic polypeptide), and (epi-)genetic lesions (e.g., K- ras and p53 mutations, p16 (INK4a) or p14 (ARF) promoter hypermethylation). In this article we discuss these new potential tumor markers for the diagnosis of CC...
  101. ncbi Cholangiocarcinoma--current treatment options
    S Friman
    Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden
    Scand J Surg 100:30-4. 2011
    ..The lack of effective medical treatment makes a radical surgical resection or hepatectomy the only therapeutic option. Most of the CCAs are unresectable at presentation and the prognosis for these patients is dismal...

Research Grants25

  1. Pathogenesis of Liver Fluke Induced Cancer in Thailand
    Paul Brindley; Fiscal Year: 2009
    ..Moreover, characterization of the nature and action of the carcinogens of O. viverrini would be of fundamental biomedical significance. ..
  2. Hepatic Arterial Flouridine and IV Bevacizumab for Primary Hepatic Malignancy
    William Jarnagin; Fiscal Year: 2008
    ..Furthermore, several important clinical issues are addressed by the proposed correlative studies, the results of which would be of broad general interest in clinical oncology. [unreadable] [unreadable] [unreadable]..
  3. Biomarkers of COX-2 inhibitors in intraductal papillary mucinous neoplasm (IPMN)
    Christian Schmidt; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  4. GROWTH REGULATION OF THE INTRAHEPATIC BILIARY TREE
    GIANFRANCO D ALPINI; Fiscal Year: 2010
    ..It is our firm belief that the results of these studies will provide information that will not only allow us to better understand cholangiocyte pathobiology but will also lead to treatments for cholestatic liver diseases. ..
  5. Occult Hepatitis B
    Michael Torbenson; Fiscal Year: 2007
    ..abstract_text> ..
  6. DIET AND DURATION OF CERVICAL HPV INFECTION
    MARC GOODMAN; Fiscal Year: 2009
    ....
  7. A Phase 1 Study of CCI-779 in Combination with Imatnib *
    RANDALL HOLCOMBE; Fiscal Year: 2006
    ..Since deregulated kinase activity is known to contribute to a wide range of malignancies, these studies will have applicability to cancer therapy in general. [unreadable] [unreadable]..
  8. EARLY DETECTION OF MENINGEAL CARCINOMATOSIS USING TOPOG*
    Sydney Finkelstein; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  9. Wnt Signaling in IBD-Related Colon Cancer
    RANDALL HOLCOMBE; Fiscal Year: 2005
    ..The precise effects of FIPs on Wnt signaling will be defined in vitro, with attention to the potentially disparate responses of different, specific, Fz receptor subtypes. ..
  10. GM-CSF Enhanced Colorectal Cancer Tumor Vaccine Program
    Richard Schulick; Fiscal Year: 2008
    ..abstract_text> ..
  11. Nonalcoholic steatohepatitis and Cytochrome P450 Enzymes
    Naga P Chalasani; Fiscal Year: 2010
    ..Additionally, we examine the relationship between this enzyme activity and the degree of insulin resistance and lipid peroxidation. ..
  12. Pathophysiological Interpretations of Dynamic PET/CT of Molecular Liver Biology
    Susanne Keiding; Fiscal Year: 2010
    ..This will lead to improved diagnosis and treatment of the large groups of patients with liver disease and cancer in the liver. ..
  13. GLYCOCONJUGATES IN PANCREATIC CANCER
    Young Kim; Fiscal Year: 2002
    ..It is hoped that these studies will facilitate the development of novel approaches to both the early diagnosis and treatment of pancreatic cancer. ..
  14. FDG PET-CT in Metastatic Prostate Cancer
    Hossein Jadvar; Fiscal Year: 2010
    ..Rigorous statistical methods will be applied to determine the diagnostic and prognostic performance of FDG PET-CT in this clinical setting. ..
  15. Evaluation of Biliary Strictures by IDUS, DIA, and FISH
    Michael Levy; Fiscal Year: 2005
    ..Significance: The study results have the potential to significantly improve the accurate diagnosis of biliary strictures. Earlier and more definitive diagnosis will translate into improved treatment options. ..
  16. Computer Aided Liver Lesion Detection Algorithm
    Lawrence Schwartz; Fiscal Year: 2005
    ..Clearly this is the first step in a process of development and if successful will lead to further efforts in automated detection and characterization. ..
  17. Ischemic Stroke Treatment with Microbubbles, a Novel Clot Lysis Therapeutic
    William C Culp; Fiscal Year: 2010
    ..Our proposed pilot study will determine which of these treatments is most successful, and future studies will further explore that treatment. (End of Abstract) ..
  18. Gene Expression in Barrett's Esophagus
    Hashem El Serag; Fiscal Year: 2006
    ..We present preliminary data on microarray and RT-PCRanalyses on 5 patients with BE that suggest an overactive Wnt pathway: we have also assembled the essential components of a successful study using microarrays. ..
  19. Real-time in Vivo Dosimetry in Radiation Therapy Using Scintillation Detectors
    Sam Beddar; Fiscal Year: 2009
    ..The resulting data can also be used to study dose- related treatment side effects. The ultimate goal of utilizing this method is to improve the delivery of radiotherapy treatments and the quality of life of radiotherapy patients. ..
  20. Listeria Monocytogenes to Treat Hepatic Metastases
    Richard Schulick; Fiscal Year: 2009
    ..Specific Aim 4: Define the role of dendritic cells in the priming and targeting of the immune response. ..
  21. Targeting AKT as a novel therapy in pancreatic cancer
    Richard Bold; Fiscal Year: 2007
    ..These results will provide mechanistic as well as pre-clinical data in support of our hypothesis and will allow for the development of novel therapy of human pancreatic cancer. [unreadable] [unreadable] [unreadable]..
  22. Image-guided catheter biopsy of peripheral lung cancer
    Eric Seibel; Fiscal Year: 2005
    ..abstract_text> ..
  23. Pixel-accurate oncologic therapy using a scanning fiber endoscope
    Eric J Seibel; Fiscal Year: 2010
    ..abstract_text> ..
  24. CatheterScope for Intraluminal Image of Early.Neoplasia
    Eric Seibel; Fiscal Year: 2006
    ..abstract_text> ..
  25. Surveillance for Hepatocellular Carcinoma among HCV-infected Veterans
    Hashem El Serag; Fiscal Year: 2009
    ..Evaluating the extent and patterns of HCC surveillance is crucial in understanding diffusion (and obstacles) of this practice and in designing interventions to improve the implementation of HCC surveillance. ..